UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 13, 2015

 

 

FATE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

001-36076

 

65-1311552

(State or other jurisdiction of

incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

3535 General Atomics Court, Suite 200

San Diego, CA 92121

(Address of principal executive offices, including zip code)

 

(858) 875-1800

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o                 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 5.07                                           Submission of Matters to a Vote of Security Holders.

 

The following proposals were submitted to the stockholders at the 2015 Annual Meeting of Stockholders held on May 13, 2015:

 

(i) The election of three Class II directors, as nominated by the Board of Directors, to hold office until the 2018 Annual Meeting of Stockholders or until their successors are duly elected and qualified; and

 

(ii) The ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2015.

 

The proposals are described in detail in the Company’s Proxy Statement filed with the Securities and Exchange Commission on April 2, 2015.

 

The number of shares of common stock entitled to vote at the annual meeting was 20,637,217.  The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 17,624,815.  All matters submitted to a vote of the Company’s stockholders at the Annual Meeting were approved and all director nominees were elected.

 

The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below:

 

(a)                                 Election of Class II Directors.

 

Director Nominee

 

Votes For

 

Votes Withheld

Mark J. Enyedy

 

13,168,853

 

17,374

Amir Nashat, Sc.D.

 

13,183,143

 

3,084

William H. Rastetter, Ph.D.

 

13,150,914

 

35,313

 

There were 4,438,588 broker non-votes regarding the election of directors.

 

(b)                                 Ratification of Auditors.

 

Stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2015.  The results of the voting included 17,582,653 votes for, 39,744 votes against, and 2,418 votes abstained.

 

There were zero broker non-votes regarding this proposal.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 15, 2015

Fate Therapeutics, Inc.

 

 

 

 

 

 

 

By:

/s/ J. Scott Wolchko

 

 

J. Scott Wolchko

 

 

Chief Financial Officer and Chief Operating Officer

 

3